Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$15.48
+0.3%
$14.01
$7.86
$17.75
$1.84B1.772.15 million shs948,048 shs
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
$36.21
+1.3%
$33.06
$23.15
$40.88
$1.80B0.77339,749 shs120,120 shs
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$18.35
+2.7%
$15.52
$8.91
$18.90
$1.76B0.91.36 million shs1.81 million shs
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
$18.60
+0.3%
$17.02
$11.56
$29.79
$476.21M2254,470 shs85,549 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
+0.19%+8.51%+15.15%+18.60%+44.61%
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
+1.68%+3.35%+8.60%+25.80%-13.86%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
+1.77%-0.17%+17.88%+20.09%+57.58%
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
-0.11%+7.48%-2.27%+15.80%+16.02%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
1.2812 of 5 stars
2.41.00.00.02.51.70.6
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
1.3363 of 5 stars
3.30.00.00.01.62.50.0
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
2.8613 of 5 stars
3.61.00.00.02.24.20.6
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
1.9892 of 5 stars
3.51.00.00.02.52.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
2.83
Moderate Buy$18.8021.45% Upside
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
2.55
Moderate Buy$58.8962.63% Upside
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
3.17
Buy$31.0068.94% Upside
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
3.00
Buy$49.33165.23% Upside

Current Analyst Ratings Breakdown

Latest TRML, IMCR, ARQT, and SPRY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2025
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$100.00
5/27/2025
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$65.00
5/23/2025
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
5/8/2025
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$85.00 ➝ $86.00
5/5/2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$70.00 ➝ $70.00
5/5/2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
4/23/2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$70.00
(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$196.54M9.39N/AN/A$1.35 per share11.47
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
$333.58M5.45N/AN/A$7.20 per share5.03
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$97.12M18.56$0.01 per share2,073.62$2.64 per share6.95
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
N/AN/AN/AN/A$11.71 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-$140.04M-$1.04N/AN/AN/A-60.95%-80.66%-32.94%8/13/2025 (Estimated)
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
-$51.09M-$0.43N/AN/AN/A-6.48%-5.86%-2.09%8/6/2025 (Estimated)
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$8M-$0.16N/AN/AN/A-16.11%-6.94%-5.60%8/5/2025 (Estimated)
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
-$73.21M-$3.21N/AN/AN/AN/A-26.75%-26.11%8/6/2025 (Estimated)

Latest TRML, IMCR, ARQT, and SPRY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
-$0.21N/AN/AN/AN/AN/A
8/14/2025Q2 2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
-$0.95N/AN/AN/AN/AN/A
8/13/2025Q2 2025
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-$0.19N/AN/AN/A$72.70 millionN/A
8/5/2025Q2 2025
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-$0.42N/AN/AN/A$12.92 millionN/A
5/14/2025Q1 2025
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-$0.35-$0.35N/A-$0.35$7.48 million$7.97 million
5/7/2025Q1 2025
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
-$0.35$0.10+$0.45$0.10$108.82 million$125.13 million
5/6/2025Q1 2025
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-$0.21-$0.20+$0.01-$0.20$64.80 million$65.85 million
5/2/2025Q1 2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
-$0.91-$0.89+$0.02-$0.89N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
N/AN/AN/AN/AN/A
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
N/AN/AN/AN/AN/A
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
N/AN/AN/AN/AN/A
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
0.75
3.55
3.37
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
1.03
6.36
6.31
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
0.30
11.00
10.74
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
N/A
33.87
33.87

Institutional Ownership

CompanyInstitutional Ownership
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
N/A
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
84.50%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
68.16%
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
91.89%

Insider Ownership

CompanyInsider Ownership
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
9.40%
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
10.40%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
33.50%
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
13.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
150119.20 million108.00 millionOptionable
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
32050.23 million45.01 millionOptionable
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
9098.21 million65.31 millionOptionable
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
4425.69 million22.35 millionOptionable

Recent News About These Companies

Tourmaline Bio Inc News (TRML) - Investing.com
TRML - Tourmaline Bio Inc Dividends - Morningstar
TRML - Tourmaline Bio Inc Executives - Morningstar
Tourmaline Bio initiated with a Buy at Chardan
Tourmaline Bio (TRML) Gets a Buy from Chardan Capital

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arcutis Biotherapeutics stock logo

Arcutis Biotherapeutics NASDAQ:ARQT

$15.48 +0.05 (+0.32%)
Closing price 04:00 PM Eastern
Extended Trading
$15.54 +0.05 (+0.36%)
As of 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Immunocore stock logo

Immunocore NASDAQ:IMCR

$36.21 +0.47 (+1.32%)
Closing price 04:00 PM Eastern
Extended Trading
$36.20 -0.01 (-0.03%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

ARS Pharmaceuticals stock logo

ARS Pharmaceuticals NASDAQ:SPRY

$18.35 +0.48 (+2.69%)
Closing price 04:00 PM Eastern
Extended Trading
$18.13 -0.22 (-1.20%)
As of 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Tourmaline Bio stock logo

Tourmaline Bio NASDAQ:TRML

$18.60 +0.06 (+0.32%)
Closing price 04:00 PM Eastern
Extended Trading
$19.13 +0.53 (+2.85%)
As of 06:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.